Alkem Laboratories inches up on launching NeuCeno for treatment of partial-onset seizures in adult patients
Alkem Laboratories is currently trading at Rs. 5159.50, up by 4.50 points or 0.09% from its previous closing of Rs. 5155.00 on the BSE.
The scrip opened at Rs. 5246.00 and has touched a high and low of Rs. 5265.70 and Rs. 5,149.45 respectively. So far 53223 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 5933.00 on 13-Jan-2026 and a 52 week low of Rs. 5052.05 on 11-Sep-2026.
Last one week high and low of the scrip stood at Rs. 5290.00 and Rs. 5052.05 respectively. The current market cap of the company is Rs. 61689.56 crore.
The promoters holding in the company stood at 49.70%, while Institutions and Non-Institutions held 33.04% and 17.25% respectively.
Alkem Laboratories has launched NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets.
Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition. Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life.
